Paul Orlady’s factory has no loading dock, no forklifts and, at its most important scale, no room for a foreman. It sits inside a microbial cell. The raw material is ordinary sugar. The workers are enzymes. The intended products are complex natural compounds that plants make sparingly and conventional biosynthesis can struggle to assemble without detours. Khona Scientific, the Colorado company Orlady co-founded and leads, proposes to impose some order on the bustle.
The company calls its platform BiDS. The friendly translation is “molecular assembly line.” Instead of allowing each enzyme and intermediate to find the next reaction through the crowded interior of a cell, the system arranges a multi-step pathway into a more useful sequence. Biology remains biology - restless, conditional and unimpressed by a pitch deck - but the architecture is meant to reduce diffusion, side reactions, bottlenecks and waste.
Orlady is an interesting person to place at the commercial end of this proposition. His public biography begins not with a pipette but with economics. He attended Gonzaga University from 1981 to 1985, earned a bachelor’s degree in the subject and ran men’s cross country. Decades later he appeared as a principal of Enterprise Risk Strategies, a Colorado consultancy. Now he is president and chief executive of a synthetic-biology venture. The scenery changed. The governing question did not: where does a system lose value, and what happens if its parts are put in a better order?
An economist at the enzyme shop
A biotechnology chief executive does not need to be the person designing every construct at the bench. Khona’s founding team divides the work. Paul Orlady runs the company; Jordan Buck holds the scientific brief; Dylan Orlady oversees operations. It is a small-team arrangement in which commercial discipline has nowhere to hide. Patents, equipment, financing, partnerships and the weekly realities of a laboratory all arrive at the same modest table.
The economics of complex biosynthesis can become rude very quickly. A pathway with only a few reactions may behave nicely. Add many more and every handoff is an invitation to lose material. An intermediate wanders away. An unwanted reaction claims it. A molecule becomes awkward for the host cell. A costly reagent turns an elegant experiment into an unattractive product. Even successful fermentation leaves separation and purification waiting at the end, tapping a watch.
“The company is not merely asking yeast to work harder. It is rearranging the shop floor.”YesPress analysis of the BiDS design
Khona chose a demanding early test: cannabinoid pathways that it describes as requiring more than 20 biological steps. The point was not the fashion of the ingredient. It was the inconvenience of the route. If an organizing system could improve a pathway this long, it might travel to other valuable natural compounds that are scarce, expensive to extract or exposed to fragile sourcing.
Those figures are company-reported milestones, not a victory parade. Orlady’s own public update about new equipment was careful: the addition would let Khona scale and optimize several biosynthesis platforms to 300-liter production capacity. The verb “demonstrate” did the honest work. A larger vessel is an opportunity to collect evidence. It is not evidence by itself.
The market grew more serious
Khona’s public language has widened. The early material leaned heavily on rare compounds and consumer ingredients. The newer language emphasizes pharmaceutical key starting materials, active ingredients and regional manufacturing. The technology story stayed recognizable; the commercial target moved upstream into supply chains where a missing input can idle everything after it.
This is the portion of Orlady’s job that resembles risk management in a lab coat. A supply chain can fail because a port closes, a policy changes or a distant supplier has no convenient substitute. A biosynthetic pathway can fail because one reaction cannot keep pace with the next. In each case, concentration and weak handoffs turn ordinary trouble into a system-wide problem. Khona’s wager is that a modular fermentation route can provide another option for selected complex compounds.
The company has spent 2026 attaching that wager to institutions with different kinds of leverage. It announced a letter of intent with Benuvia Operations to evaluate biosynthetic routes within demanding manufacturing requirements. It joined the BioMaP Consortium, a network concerned with U.S. biomanufacturing readiness. It added Michael A. Gonzalez, a veteran of green chemistry and industrial process work, to its board. It also announced another exploratory relationship around a purpose-built production pipeline. Each move supplies context that a four-person team cannot manufacture alone.
The distinction between exploration and production matters. A letter of intent is a framework for evaluation, not a purchase order. Consortium membership creates access and conversation, not automatic government funding. A board appointment adds judgment, not instant scale. Orlady’s public role is to move these modest nouns in the right sequence until, perhaps, they become larger verbs.
Sell the transition
Khona’s partner model is unusually legible. It begins with proof of concept and compound-specific intellectual property. Then comes scale and optimization. Finally, a program can move toward commercial production, licensing or some combination. The structure gives an early company ways to create value before it owns every stainless-steel tank it might one day require.
There is a useful lesson here for founders far outside biotechnology. When the final destination is expensive, distant and uncertain, sell the resolved uncertainty along the way. A customer may not be ready to buy a factory’s output. It may be ready to buy a proof, an optimization program or an alternative route. Each rung can finance knowledge required by the next.
The financing record tells a similarly incremental story. Public filings list debt and equity offerings over several years, including a $340,000 convertible-note offering filed in 2025. The sums are meaningful for a tiny company but modest beside the appetite of industrial biotechnology. Khona therefore has reason to remain flexible: development work, intellectual-property licensing and partnerships can extend a platform without forcing Orlady to fund every vessel, technician and quality system alone.
“We look forward to further demonstrating the capabilities of the patented BiDS synthetic biology platform.”Paul Orlady, on Khona’s equipment expansion
The examination begins after the metaphor
“Molecular assembly line” is a very good phrase. It makes an invisible architecture visible. It is also where the easy part of the explanation ends. The difficult proof is repeatability: whether an organized pathway holds its performance as volume rises, whether the target can be recovered cleanly, whether batches meet the same specification and whether the total cost competes with extraction or chemical synthesis.
Orlady’s economics degree becomes relevant again at this stage. Sugar can be inexpensive while reactors, chromatography media, trained staff, validation and quality systems are emphatically not. Yield is only one line in the ledger. Throughput matters. Batch time matters. Purification matters. The price a customer will pay has the last word, delivered without italics.
Khona’s selection problem is therefore as important as its engineering. The best targets are complex enough to benefit from pathway organization, valuable enough to tolerate downstream work, difficult enough that incumbents leave room, and exposed enough that a second source carries strategic value. Cheap bulk chemicals with excellent existing routes are unlikely to applaud. A rare, awkward compound with unreliable supply may be more receptive.
What makes Orlady’s story personal is not a laboratory epiphany available in a neat anecdote. It is the continuity of his operating lens. He ran long distances at Gonzaga, studied incentives and scarcity, built a career around enterprise risk and arrived at a company where the central invention is a disciplined sequence. The biography has the geometry of its product: progress by placing one step where the next can use it.
The next persuasive milestones will be pleasantly uncinematic. A stable yield at larger scale. A purification process whose costs behave. A definitive agreement rather than an exploratory one. A named material delivered repeatedly to specification. These are not the moments that make good launch videos. They are the moments that make a biotechnology business.
Until then, Paul Orlady leads a compact Colorado company carrying a large industrial hypothesis. Ordinary yeast has been making useful things for civilization for a very long time. Khona would like to give it a more demanding shift, a tidier workstation and a sequence worth following. If the economics cooperate, the smallest factory may earn a place in a much larger supply chain.